Foghorn Therapeutics Inc. announced on December 16, 2024, its decision to discontinue the independent development of FHD-286 in combination with decitabine for patients with relapsed and/or refractory acute myeloid leukemia (AML). While objective clinical responses were observed in the Phase 1 dose escalation trial, the observed response rate did not meet the company’s threshold for continued independent development.
The company stated it will prioritize investment into its proprietary pipeline, including the Selective CBP program, Selective EP300 program, and ARID1B program. Additionally, Foghorn will increase focus on its collaboration programs with Eli Lilly, specifically the clinical-stage selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784).
As of September 30, 2024, Foghorn reported $267.4 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2027. This strategic decision to streamline its pipeline is intended to optimize resource allocation towards programs with higher potential for success and greater alignment with its long-term goals.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.